Science
Mechanism of Action
Functions as an antifibrinolytic agent that competitively inhibits plasminogen activation and plasmin activity in skin tissue. By blocking these proteolytic enzymes and specifically targeting Kallikrein 5 (KLK5), it helps stabilize the skin barrier matrix and reduces inflammation associated with protease overactivity, particularly beneficial for rosacea-prone skin.
Research
Clinical Evidence
Medium confidence0.001%
Key findings
- 01 25% concentration investigated for rosacea treatment via KLK5 inhibition (ClinicalTrials.gov NCT01398280)
- 02 0.001% in amino acid complex demonstrated significant skin repair, redness reduction, and moisturization enhancement (J Cosmet Dermatol 2021)
Transparency
Dusting Analysis
Effective concentrations start as low as 0.001%, making dusting less likely. However, formulations below 0.0005% may provide insufficient therapeutic benefit given the specific enzyme inhibition mechanism required.
The Formula
Formulation
Stability
Exceptionally water-soluble (330-500 mg/mL) with excellent stability in light and air. As a zwitterionic compound, solubility decreases near its isoelectric point of 7.6, requiring careful pH management.
Synergies
- other amino acids
- barrier repair peptides
- anti-inflammatory actives
Conflicts
- strong oxidizing agents
Safety
Safety Profile
CIR-reviewed as part of alpha-amino acids group with established safety profile. FDA-approved for systemic use as hemostatic agent, indicating robust safety data.
Your Skin
Skin Compatibility
Our Assessment
Verdict
A scientifically-backed amino acid with proven anti-inflammatory properties and excellent safety profile, particularly valuable for sensitive and rosacea-prone skin at very low concentrations.
Related
Similar Ingredients
Finding similar ingredients…
References
Sources